Alpha Cognition gets FDA approval for ZUNVEYL to treat mild-to-moderate Alzheimer's

Alpha Cognition Inc.

FDA approved ZUNVEYL (benzgalantamine) for mild-to-moderate Alzheimer's disease; second oral AD therapy approved this decade.
GI adverse events under 2% and no insomnia observed in bioequivalence studies, designed to bypass GI absorption.
Commercial availability planned in pharmacies nationwide starting Q1 2025.
CEO Michael McFadden called approval a major breakthrough; company targets tolerability issues leading to 55% discontinuation rate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.